The Project on microdosing & MDMA therapy

projecttv.sb_.dec16

The Project covers Microdosing & MDMA therapy with Dr Stephen Bright (NDRI & PRISM), Dr Tony Bartone (AMA Vice president) & Vironika Drago (Slater & Gorend. While it does provide some positive positioning of psychedelics through the consumers they interviewed, the overall story is positioned within the pathological paradigm. Producer: Julie Holmes

Unfortunately there was some misinformed discussion by The Project’s presenters towards the end of this segment. It should be noted that the classic psychedelics used for microdosing (LSD and psilocybin) are not addictive. Typically microdosing occurs every third day, not daily.

 

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Innovative psychedelic research

The re-emergence of psychedelic research places a crucial emphasis on a holistic approach to mental health from pharmacology, neurobiological process, ecological connection, and therapeutic support.  PRISM supports research and clinical development of therapies where current options provide limited relief.

Your support allows us to pursue cutting edge research for next-generation mental health care.

PRISM

We are a DGR-1 non-profit research charity developing medical and legal processes for the application of psychedelic medicines for improved wellbeing.

Newsletter

Contact Us

Send us an email and we'll get back to you soon.

Not readable? Change text. captcha txt

Start typing and press Enter to search